Hypertension and diabetic nephropathy

Endocrine Development

Volumn 31, Issue , 2016, Pages 97-107

  Skov, Jeppe ^a   Christiansen, Jens Sandahl ^a   Poulsen, Per Løgstrup ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; GLUCOSE BLOOD LEVEL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; ANALYSIS; COMPLICATION; DIABETIC NEPHROPATHIES; GLUCOSE BLOOD LEVEL; HYPERTENSION, RENAL;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION, RENAL;

EID: 84956637758     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000439393     Document Type: Article

References (43)

1. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936; 12: 83-98.
2. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Ding S, Guo H, Kats A, Lamb K, Li S, Li S, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Weinhandl E, Xiong H, Yusuf A, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. US renal data system 2012 annual data report. Am J Kidney Dis. 2013; 61: A7, e1-e476.
3. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008; 117: 1945-1954.
4. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. New Engl J Med. 2011; 364: 829-841.
5. Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, Rosengard-Barlund M, Saraheimo M, Hietala K, Heikkila O, Forsblom C. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58: 1651-1658.
6. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. New Engl J Med. 1984; 311: 89-93.
7. Christiansen JS. Glomerular hyperfiltration in diabetes mellitus. Diabet Med. 1985; 2: 235-239.
8. Poulsen PL, Ebbehoj E, Hansen KW, Mogensen CE: 24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia 1997 40 718-725.
9. Hansen KW, Sorensen K, Christensen PD, Pedersen EB, Christiansen JS, Mogensen CE. Night blood pressure: relation to organ lesions in microalbuminuric type 1 diabetic patients. Diabet Med. 1995; 12: 42-45.
10. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo- To microalbuminuria. A longitudinal study in IDDM patients. Diabetes. 1994; 43: 1248-1253.
11. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. New Engl J Med. 2002; 347: 797-805.
12. Rossen NB, Knudsen ST, Fleischer J, Hvas AM, Ebbehoj E, Poulsen PL, Hansen KW. Targeting nocturnal hypertension in type 2 diabetes mellitus. Hypertension. 2014; 64: 1080-1087.
13. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011; 34: 1270-1276.
14. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317: 703-713.
15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med. 2001; 345: 861-869.
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New Engl J Med. 1993; 329: 1456-1462.
17. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med. 2001; 345: 870-878.
18. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. New Engl J Med. 2009; 361: 40-51.
19. Haller H, Ito S, Izzo JL, Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med. 2011; 364: 907-917.
20. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-Angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-Analysis. BMJ. 2013; 347: f6008.
21. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med. 2008; 358: 1547-1559.
22. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, OConnor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. New Engl J Med. 2013; 369: 1892-1903.
23. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New Engl J Med. 2012; 367: 2204-2213.
24. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434-444.
25. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829-840.
26. Cushman WC, Evans GW, Byington RP, Goff DC, Jr, Grimm RH, Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med. 2010; 362: 1575-1585.
27. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. New Engl J Med. 2013; 368: 1613-1624.
28. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New Engl J Med. 2011; 365: 2366-2376.
29. DCCT/EDIC Research Group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-Term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014 2 793-800.
30. Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl. 2011; 120: S28-S32.
31. Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014; 15: 197-207.
32. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New Engl J Med. 2013; 369: 1317-1326.
33. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res. 2012; 35: 483-488.
34. Imamura S, Hirai K, Hirai A. The glucagon-like Peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013; 231: 57-61.
35. Hirata K, Kume S, Araki S-I, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009; 380: 44-49.
36. Ishibashi Y, Matsui T, Ojima A, Nishino Y, Nakashima S, Maeda S, Yamagishi S. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res. 2012; 84: 395-398.
37. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, Nishikawa S, Rask-Madsen C, King GL. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes. 2012; 61: 2967-2979.
38. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and reninangiotensin-Aldosterone system in healthy men. J Clin Endocrinol Metab. 2013; 98: E664-E671.
39. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013; 345: 464-472.
40. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H. Long-Term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PloS One. 2014; 9: e100777.
41. Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One. 2014; 9: e108994.
42. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-597.
43. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014; 16: 1016-1027.